PEG-somatropin
ApprovedUNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency
Conditions
Growth Hormone Deficiency
Trial Timeline
Jan 1, 2015 → —
NCT ID
NCT03249480About PEG-somatropin
PEG-somatropin is a approved stage product being developed by Sun Pharmaceutical for Growth Hormone Deficiency. The current trial status is unknown. This product is registered under clinical trial identifier NCT03249480. Target conditions include Growth Hormone Deficiency.
What happened to similar drugs?
10 of 20 similar drugs in Growth Hormone Deficiency were approved
Approved (10) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03249480 | Approved | UNKNOWN |
| NCT01495468 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency